Zobrazeno 1 - 10
of 24
pro vyhledávání: ''
Autor:
Xiaohui Wang, Karthik Venkatakrishnan, Elliot Offman, Michael J. Hanley, Neeraj Gupta, David Kerstein, Marita Prohn, Narayana I. Narasimhan
Publikováno v:
Clinical Pharmacokinetics
Background and objectives Brigatinib is an oral tyrosine kinase inhibitor approved in multiple countries for the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer who have progressed on or are intole
Autor:
Joseph W. Chow, Angela Wardman, David Wilson, Helen Broadhurst, Paul Newell, Katrina Yates, Karen Cheng
Publikováno v:
Drug Safety
Introduction Ceftazidime–avibactam combines the established anti-pseudomonal cephalosporin, ceftazidime, with the novel non-β-lactam β-lactamase inhibitor, avibactam. Objectives The aim of this study was to evaluate the safety of ceftazidime–av
Autor:
Carol Cronenberger, Sarah Hackley, Hideto Kameda, Sebastião Cezar Radominski, Muhammad I. Rehman, Rieke Alten, Michael L. Tee, Alan Kivitz, Stanley Cohen, Oliver von Richter, Min Zhang
Publikováno v:
Biodrugs
Objective Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid arthritis (RA) who continued biosimilar treatment throughout 78 weeks
Autor:
Alexander C. Schmidt, Gael Dos Santos, Tamara Eckermann, Xavier Martínez-Gómez, Vishvesh Shende, Ignacio Salamanca de la Cueva, Lode Godderis, Hugo Loos, Bach-Yen Nguyen, Silvia Damaso, Anne Yeakey
Publikováno v:
Drug Safety
INTRODUCTION: Seasonal influenza causes numerous deaths worldwide each year. Annual vaccination for disease prevention is crucial. Seasonal vaccines are updated each year to closely match circulating strains. OBJECTIVE: To comply with European Medici
Publikováno v:
Clinical Pharmacokinetics
Risankizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody developed and approved for the treatment of moderate-to-severe plaque psoriasis at a dose of 150 mg administered subcutaneously at weeks 0 and 4, and every 12 weeks thereafter. On
Autor:
Igor Bondarenko, Maciej Bryl, Kazuo Kasahara, Vladimir Ivanovich Vladimirov, Manuela Zereu, Kostas N. Syrigos, Niels Reinmuth, Angel H. Bair, Fiona Hilton, K. F. Liau
Publikováno v:
Biodrugs
Background PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin®) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in the first-lin
Autor:
Simon Zhou, Yan Li, Kathryn Newhall, Richard Delarue, Stephen E. Maxwell, Vitalina Komashko, Steven Novick, Justine Dell’Aringa, Myron S. Czuczman, Shelonitda Rose, Nurgul Kilavuz, C. L. Beach, Maria Palmisano, Lars Sternas, Ken Ogasawara
Publikováno v:
Clinical Pharmacokinetics
Background and Objectives Durvalumab, a human monoclonal antibody targeting programmed cell death ligand 1, has been approved for urothelial carcinoma and stage III non-small cell lung cancer by the US Food and Drug Administration and is being evalua
Publikováno v:
Clinical Pharmacokinetics
Background and Objective Sarilumab binds to the interleukin-6 receptor with high affinity, inhibiting cis and trans signaling by interleukin-6. Sarilumab has demonstrated efficacy and safety in patients with rheumatoid arthritis. The objective of thi
Autor:
Ahmed A. Othman, Ben Klünder, Peter Noertersheuser, Mohamed-Eslam F. Mohamed, Anna Friedel, Rajendar K. Mittapalli
Publikováno v:
Clinical Pharmacokinetics
Background and Objectives Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed as an orally administered treatment for patients with moderate to severe rheumatoid arthritis (RA) and other autoimmune disorders. These analyses cha
Autor:
Alfredo Berrocal Kasay, Thomas Linde, Piotr Wiland, Elia Chalouhi El-Khouri, Sang Joon Lee, Pavel Shesternya, Francisco Fidenci Cons Molina, Janusz Jaworski, Ihor Hospodarskyy, Paweł Hrycaj, Jose Chavez-Corrales, Mauricio Abello-Banfi, Marek Brzosko, Sergii Shevchuk, Seung Cheol Shim, Dae Hyun Yoo, Armando Calvo, D. Andersone, Sławomir Jeka, Chang-Hee Suh, Sung Young Lee, Francisco G. Medina-Rodriguez, Pedro Miranda, Marek Krogulec, Won Park, Mariusz Piotrowski
Publikováno v:
Biodrugs
Objective The aim of this study was to investigate long-term clinical outcomes of extended treatment with CT-P10, a rituximab biosimilar, compared with rituximab reference products sourced from the USA and the EU (US-RTX and EU-RTX) in rheumatoid art